A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was what the optimal intraoperative anticoagulation strategy should be in patients undergoing off-pump coronary artery bypass graft (CABG) surgery. A total of 157 papers were identified using the reported search, of which 8 were judged to represent the best evidence. The authors, journal, date, country of publication, study type, patient group studied, relevant outcomes and results were tabulated. The quality of clinical trials was assessed. Off-pump CABG is currently considered as a safe and effective alternative to CABG with the use of cardiopulmonary bypass, especially in the presence of off-pump expertise and certain pathologies. Although most technical steps in off-pump revascularization are standardized, it appears that there is inconsistency in intraoperative anticoagulation practice. Surveys conducted in the USA and Europe confirm the lack of uniform policy, with heparin dose ranging between 70 and 500 U/kg and from full-dose protamine to no reversal of anticoagulation. Although the quality of evidence is low, there is a trend for utilization of heparin at 150 U/kg, followed by half-dose protamine reversal, which appears to provide adequate anticoagulation for the safe conduct of anastomoses and thromboprophylaxis without significantly increasing the risk of postoperative bleeding. However, more research is necessary before firm recommendations can be made.
INTRODUCTION
A best evidence topic was written according to a structured protocol [1] .
THREE-PART QUESTION

In patients undergoing [off-pump CABG] which [intraoperative anticoagulation strategy] confers [optimal results]?
CLINICAL SCENARIO
You reviewed a patient with stable angina and distal left main stem disease, and a decision was taken to proceed with inpatient CABG without cardiopulmonary bypass. You inform the duty anaesthetist who is experienced in off-pump surgery, whom you have not worked with before. After you discuss the clinical case and planned revascularization strategy, he asks you about intraoperative anticoagulation. You say that you request for full heparinization (similar to on-pump CABG) followed by complete reversal with protamine. He claims that his anticoagulation strategy is different, since half-dose heparin may be similarly efficacious in preventing graft thrombosis, cause less intraoperative bleeding and avoid the use of protamine with its potential adverse effects. You have decided to look at the available evidence and communicate this further before the procedure.
SEARCH STRATEGY
PubMed search form 1948 to October 2011 using the following criteria (off-pump coronary artery bypass or beating heart coronary artery bypass) and (heparin or anticoagulation or heparinization or protamine).
SEARCH OUTCOME
A total of 157 papers were found, of which 8 were identified to provide the best evidence (Table 1) .
RESULTS
In CABG with the use of cardiopulmonary bypass, routine anticoagulation consists of heparin ≥300 U/kg, aiming at activated clotting time (ACT) of ≥400 s [2, 3] . In addition to the possible procoagulant affliction occurring in the first 24 h following off-pump CABG (OPCAB) [4] , the absence of 'pump effect' on coagulation means that principles of anticoagulation used for on-pump CABG may not apply in OPCAB. Currently, there are Heparin dose 150 U/kg is insufficient and can lead to a higher bleeding and thrombotic complications rate. This study provides support for using high-dose heparin Randomized trial Jadad: 2 Anticoagulation protocol: Group 1 (n = 76) received heparin dose 150 U/kg, and given additional 5000 U as required bolus during the procedure to maintain the ACT of >300 s
ACT levels
Greater standard deviation from the mean for ACT in low-vs. high-dose patients (95 s vs. 55 s).
Group 2 (n = 76) received heparin dose 300 U/kg, and additional heparin 5000 U as required bolus to maintain the ACT of >400 s [5] conducted a postal survey in the USA and Canada to determine OPCAB anticoagulation practices. They showed that 54% used half dose with the majority (70%) aiming for ACT levels between 300 and 400 s. Sixty per cent of surgeons used full protamine for reversal. In addition, 84% of surgeons believed that partial heparinization is associated with reduced intraoperative bleeding.
The concept of variable anticoagulation reversal was examined by Gatti and Pugliese [6] . In patients undergoing OPCAB with similar heparin anticoagulation, reversal was performed with three different regimes; full reversal, partial reversal and, lastly, no reversal. The total chest drain output was significantly lower in the full reversal compared with the no protamine group, but there was no significant difference between those who received full and partial protamine reversal. Concurrently, blood transfusion requirements were significantly increased in the no protamine group when compared with the fully reversed group. Donias et al. [7] investigated the effect of full vs. half-dose heparin on intraoperative graft patency in minimally invasive direct coronary artery bypass. Patients received heparin at 150 U/kg (Group 1) or 300 U/kg (Group 2) with additional boluses to maintain target ACT. Patients in Group 1 had greater variation in the ACT and required more additional heparin. The number of revised grafts was smaller in Group 2 and a thrombus at the site of anastomosis was identified in all of them. Similarly, all noncoronary thrombotic complications occurred solely in Group 1.
An observational study by Woo et al. [8] examined the effect of reduced protamine on clinical outcomes after OPCAB. Full heparin anticoagulation (aiming at an ACT of 400-450 s) was followed by 50% of protamine. This regime normalized the ACT in 95% of patients. The mean chest drain output was comparable with that of other studies where complete protamine was utilized. There was no need for blood or product transfusion, or re-explorations. These data suggest that half-dose protamine safely reverses heparin without increasing postoperative bleeding.
The anticoagulation practice in Nordic countries was assessed in a survey by Hensen et al. [9] . Twenty-four per cent reported using full-dose heparin (≥300 U/kg), 32% used half dose and 28% used one-third dose of heparin. Target intraoperative ACT also varied, with 21% maintaining ACT levels of ≥400 s, 37.5% aiming for ≥300 s and 37.5% for ≥200 s. Complete heparin reversal was used in 38% of cases, half dose in 29% of cases and 25% used variable protamine dose. This study further confirms the lack of standardized anticoagulation pattern in OPCAB, although the majority of surgeons appear to use half-dose heparinization, followed by complete protamine reversal with satisfactory results.
Tanaka et al. [2] assessed the coagulation data in 200 patients who underwent OPCAB or on-pump CABG. Patients received heparin dose 180 U/kg in OPCAB or 400 U/kg for on-pump CABG. Heparin reversal for the OPCAB was protamine 50-75 mg aiming at an ACT of 150 s (with additional 25 mg protamine if ACT > 200 s). The results of this study demonstrated that lower total doses of heparin and protamine can be administered, providing safe conduct of OPCAB, with comparable bleeding and coagulation parameters to conventional on-pump CABG.
Englberger et al. [10] performed a questionnaire survey to determine anticoagulation practice among European surgeons. The intraoperative heparin anticoagulation dose was highly variable and ranged between 70 and 500 U/kg. There was a trend towards a lower dose heparin with 60% using ≤150 U/kg and ACT levels between 200 and 250 s. For protamine reversal, 52% used full-dose protamine. Thirty-four per cent of respondents thought that OPCAB was a risk factor for early graft occlusion but the majority attributed this risk to technical challenges.
Paparella et al. evaluated the effects of half-dose (150 U/kg) vs. high-dose heparin (300 U/kg) on perioperative haemostatic changes in OPCAB [11] . The ACT immediately after heparin administration and peak levels were significantly raised in the high-dose patient group; however, biomarkers of coagulation and fibrinolysis were found to be similar. This suggests that a higher heparin dose does not translate into better control of clotting activation during OPCAB. 
CLINICAL BOTTOM LINE
Surveys assessing the patterns of anticoagulation across Europe and North America demonstrate a highly variable practice, with the choice of heparin dose depending on individual or institutional preference. Analysis of the current studies showed a trend towards half-dose heparin with ACT levels of ≥300 s, yielding satisfactory results. Although the majority of surgeons use complete protamine reversal, half-dose protocols have been shown to be equally effective without influencing postoperative bleeding. Evidence from larger randomized studies is needed to further evaluate heparin dosing, target ACT and protamine reversal and formulate robust guidelines.
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